Argireline vs Cardiogen
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
ArgirelineAnti-Aging & Longevity
Cardiogen- Summary
- Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
- Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg) developed by Professor Vladimir Khavinson. It is a tissue-specific bioregulator for the heart and myocardium, designed to normalize cardiomyocyte function and support cardiac tissue regeneration. Research has demonstrated cardioprotective effects, improved cardiac rhythm, and benefits in recovery from ischemic injury.
- Half-Life
- N/A — topical application; effect duration linked to formulation contact time
- Short (minutes); gene-regulatory effects persist longer
- Admin Route
- Topical
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 5–10% concentration
- 10 mg per day
- Frequency
- Twice daily
- Daily for 10–30 days
- Key Benefits
- Reduces depth of dynamic expression wrinkles 17–27%
- Non-invasive topical Botox alternative
- Smooths forehead, eye area, nasolabial fold lines
- Widely studied — published clinical efficacy data
- Synergistic with SNAP-8 for enhanced effect
- Reduces fine lines around eyes (crow's feet)
- Improves skin smoothness and texture
- Well tolerated across all skin types
- Cardioprotective effects on myocardial tissue
- Normalization of cardiomyocyte protein synthesis
- May improve cardiac rhythm and conduction
- Support for recovery from ischemic cardiac events
- Anti-aging effects on heart tissue
- Potential reduction in cardiac fibrosis
- Often combined with Epithalon for comprehensive cardiovascular longevity support
- Side Effects
- Generally very well tolerated
- At >10%: temporary eyelid/brow ptosis (drooping)
- Rare: mild redness in sensitive skin
- No systemic absorption at cosmetic doses
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse cardiovascular events reported at standard doses
- Stacks With
- —
- —